Serum Potassium in the PARADIGM-HF trial - Université de Lorraine Access content directly
Journal Articles European Journal of Heart Failure Year : 2020

Serum Potassium in the PARADIGM-HF trial


Background: We studied the association between potassium and outcomes, the effect of sacubitril/valsartan on potassium, and whether potassium level modified the effect of sacubitril/valsartan in patients with heart failure and a reduced ejection fraction in PARADIGM-HF.Aims: We examined several outcomes including cardiovascular death, sudden-death, pump-failure death, non-cardiovascular death and heart failure hospitalization.Methods: 8399 patients were randomized to either enalapril or sacubitril/valsartan. Potassium at randomization and follow-up was examined as a continuous and categorical variable (≤3.5, 3.6-4.0, 4.1-4.9, 5.0-5.4, and ≥5.5mmol/L) in various statistical models. Hyperkalemia was defined as K+ ≥5.5mmol/L and hypokalemia as K+ ≤3.5mmol/L.Results: Compared to potassium 4.1-4.9mmol/L, both hypokalemia (HR 2.40, 95%CI 1.84-3.14) and hyperkalemia (HR 1.42, 1.10-1.83) were associated with a higher risk of cardiovascular death. However, potassium abnormalities were similarly associated with sudden death and pump failure death, as well as non-cardiovascular death and heart failure hospitalization. Sacubitril/valsartan had no effect on potassium overall. The benefit of sacubitril/valsartan over enalapril was consistent across the range of baseline potassium.Conclusions: Although both higher and lower potassium were independent predictors of cardiovascular death, potassium abnormalities may mainly be markers rather than mediators of risk of death.
Fichier principal
Vignette du fichier
PARADIGM_K_Paper.pdf (1.06 Mo) Télécharger le fichier
PARADIGM_K_Supplement.pdf (1.15 Mo) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-02918319 , version 1 (20-08-2020)



Joao Pedro Ferreira, Ulrik M Mogensen, Pardeep Jhund, Akshay Desai, Jean-Lucien Rouleau, et al.. Serum Potassium in the PARADIGM-HF trial. European Journal of Heart Failure, 2020, 22 (11), pp.2056-2064. ⟨10.1002/ejhf.1987⟩. ⟨hal-02918319⟩
71 View
49 Download



Gmail Facebook Twitter LinkedIn More